Comparison between dutasteride and finasteride in hair regrowth and reversal of miniaturization in male and female androgenetic alopecia: a systematic review
https://doi.org/10.4081/dr.2024.9909
Accepted: 10 March 2024
SUPPLEMENTARY MATERIAL: 1
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Nowadays androgenetic alopecia (AGA) has become a common concern of affected subjects of both sexes. Finasteride is approved by the Food and Drug Administration for the treatment of male AGA. There is no clear evidence to support the use of dutasteride in male AGA. In female AGA, the effectiveness of dutasteride and finasteride is still under debate, and there is no clear evidence to use any of them in female AGA. A systematic review was conducted to compare between dutasteride and finasteride in treating both male and female AGA, and their efficacy, safety, side effects with effective dosage. The review was done using several databases including: PubMed, Ovid Medline, Google Scholar, and Cochrane using the following search terms/keywords: "Dutasteride" AND "Finasteride" AND "Male pattern hair loss" AND "Female pattern hair loss" AND "Efficacy", "Tolerability" AND "Side effects" AND "Comparison". To search for articles related to efficacy, tolerability, side effects, used doses of dutasteride and finasteride in the treatment of male and female AGA. The review encompassed a total of nine studies. Four randomized controlled trials, one single-arm trial, two prospective cohorts, and two retrospective cohort studies. Seven studies exclusively enrolled male participants, while only two included female participants. All groups receiving various doses of dutasteride and finasteride exhibited a significant increase in hair count compared to the placebo group. Notably, dutasteride (0.5 mg) and dutasteride (2.5 mg) were significantly more effective than finasteride (1 mg) in increasing hair counts. Furthermore, no significant difference in adverse events was observed between finasteride and dutasteride. Dutasteride is more potent than finasteride in treating AGA in both males and females. All the adverse events between finasteride and dutasteride were comparable.
Zhou Z, Song S, Gao Z, et al. The efficacy and safety of dutasteride compared with finasteride in treating men with androgenetic alopecia: a systematic review and meta-analysis. Clin Interv Aging 2019; Volume 14:399–406. DOI: https://doi.org/10.2147/CIA.S192435
Tsunemi Y, Irisawa R, Yoshiie H, et al. Long-term safety and efficacy of dutasteride in the treatment of male patients with androgenetic alopecia. J Dermatol 2016; 43:1051–8. DOI: https://doi.org/10.1111/1346-8138.13310
Verdonschot E, Boersma I, Oranje A, et al. The effectiveness of finasteride and dutasteride used for 3 years in women with androgenetic alopecia. Indian J Dermatology, Venereol Leprol 2014; 80:521. DOI: https://doi.org/10.4103/0378-6323.144162
Shanshanwal S., Dhurat R. Superiority of dutasteride over finasteride in hair regrowth and reversal of miniaturization in men with androgenetic alopecia: A randomized controlled open-label, evaluator-blinded study. Indian J Dermatology, Venereol Leprol 2017; 83:47. DOI: https://doi.org/10.4103/0378-6323.188652
Olsen EA, Hordinsky M, Whiting D, et al. The importance of dual 5α-reductase inhibition in the treatment of male pattern hair loss: Results of a randomized placebo-controlled study of dutasteride versus finasteride. J Am Acad Dermatol 2006; 55:1014–23. DOI: https://doi.org/10.1016/j.jaad.2006.05.007
Motofei IG, Rowland DL, Baconi DL, et al. Therapeutic considerations related to finasteride administration in male androgenic alopecia and benign prostatic hyperplasia [WWW Document]. Farmacia. 2017; 65:660–6.
Busanello EB, Turcatel E. Androgenic alopecia and dutasteride in hair mesotherapy: A short review. Our Dermatology Online 2018; 9:75–9. DOI: https://doi.org/10.7241/ourd.20181.22
Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration. PLoS Med 2009; 6:e1000100. DOI: https://doi.org/10.1371/journal.pmed.1000100
Choi GS, Kim JH, Oh S-Y, et al. Safety and Tolerability of the Dual 5-Alpha Reductase Inhibitor Dutasteride in the Treatment of Androgenetic Alopecia. Ann Dermatol 2016; 28:444. DOI: https://doi.org/10.5021/ad.2016.28.4.444
Eun HC, Kwon OS, Yeon JH, et al. Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: A randomized, double-blind, placebo-controlled, phase III study. J Am Acad Dermatol 2010; 63:252–8. DOI: https://doi.org/10.1016/j.jaad.2009.09.018
Jung JY, Yeon JH, Choi JW, et al. Effect of dutasteride 0.5 mg/d in men with androgenetic alopecia recalcitrant to finasteride. Int J Dermatol 2014; 53:1351–7. DOI: https://doi.org/10.1111/ijd.12060
Moftah N, Moftah N, Abd-Elaziz G, et al. Mesotherapy using dutasteride-containing preparation in treatment of female pattern hair loss: photographic, morphometric and ultrustructural evaluation. J Eur Acad Dermatology Venereol 2013; 27:686–93. DOI: https://doi.org/10.1111/j.1468-3083.2012.04535.x
Gubelin Harcha W, Barboza Martínez J, Tsai T-F, et al. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia. J Am Acad Dermatol 2014; 70:489-498.e3. DOI: https://doi.org/10.1016/j.jaad.2013.10.049
Salman KE, Altunay IK, Kucukunal NA, Cerman AA. Frequency, severity and related factors of androgenetic alopecia in dermatology outpatient clinic: hospital-based cross-sectional study in Turkey. An Bras Dermatol 2017; 92:35–40. DOI: https://doi.org/10.1590/abd1806-4841.20175241
Asfour L, Cranwell W, Sinclair R. Male Androgenetic Alopecia. , 2000URL http://www.ncbi.nlm.nih.gov/pubmed/14819896.
Yip L, Rufaut N, Sinclair R. Role of genetics and sex steroid hormones in male androgenetic alopecia and female pattern hair loss: An update of what we now know. Australas J Dermatol 2011; 52:81–8. DOI: https://doi.org/10.1111/j.1440-0960.2011.00745.x
LUDWIG E. Classification of the types of androgenetic alopecia (common baldness) occurring in the female sex. Br J Dermatol 1977; 97:247–54. DOI: https://doi.org/10.1111/j.1365-2133.1977.tb15179.x
Traish AM. Health Risks Associated with Long-Term Finasteride and Dutasteride Use: It’s Time to Sound the Alarm. World J Mens Health 2020; 38:323. DOI: https://doi.org/10.5534/wjmh.200012
Olszewska M, Rudnicka L. Effective treatment of female androgenic alopecia with dutasteride. J Drugs Dermatol 2005; 4:637–40.
Lee S, Lee Y, Choe S, Lee W. Adverse Sexual Effects of Treatment with Finasteride or Dutasteride for Male Androgenetic Alopecia: A Systematic Review and Meta-analysis. Acta Derm Venereol 2018. doi:10.2340/00015555-3035. DOI: https://doi.org/10.2340/00015555-3035
Copyright (c) 2024 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Downloads
Citations
